当前位置：Wow! eBook 医学、药学 Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition

Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition

2023-12-04 分类：医学、药学

Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition book cover

Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition

Author(s): David Rosenberg (Editor), Samuel Gershon

  • Publisher: Wiley-Blackwell
  • Publication Date: 3 Feb. 2012
  • Edition: 3rd
  • Language: English
  • Print length: 480 pages
  • ISBN-10: 9780470973769
  • ISBN-13: 0470973765

Book Description

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

  • Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.
  • Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.
  • Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.
  • Features many tables, figures and pictorials, making it highly accessible and reader friendly.

Editorial Reviews

Review

“Pharmacotherapy of Child and Adolescent Psychiatric Disorders is a book to have available on your desk, not just in your library. It provides ready access to the wealth of practical information and insight for the range of health and mental health professionals. It is highly recommended for trainees and anyone who is prescribing psychotropic medications to the pediatric population and young adults.” (Journal of Clinical Psychiatry, 7 July 2012)

From the Inside Flap

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

  • Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.
  • Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.
  • Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.
  • Features many tables, figures and pictorials, making it highly accessible and reader friendly.

From the Back Cover

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

  • Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.
  • Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.
  • Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.
  • Features many tables, figures and pictorials, making it highly accessible and reader friendly.

About the Author

David Rosenberg MD, Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children’s Hospital of Michigan, Detroit, MI , USA

Samuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA

View on Amazon

电子书代发PDF格式价格30元我要求助
未经允许不得转载：Wow! eBook » Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition

相关推荐

代查图书，纸质书扫描成PDF，电子书代购，代下载，打印装订服务

QQ:7450911

Email:girro@qq.com

Add:Beijing，China 中国，北京